Letter : optimising response to ustekinumab therapy for patients with Crohn's disease
| Errataetall: |
CommentOn: Aliment Pharmacol Ther. 2020 Jul;52(1):135-142. - PMID 32412134 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 52(2020), 5 vom: 27. Sept., Seite 906 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hudson, Joshua [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 02.11.2020 Date Revised 24.11.2020 published: Print CommentOn: Aliment Pharmacol Ther. 2020 Jul;52(1):135-142. - PMID 32412134 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.15961 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314260749 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314260749 | ||
| 003 | DE-627 | ||
| 005 | 20231225152340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.15961 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314260749 | ||
| 035 | |a (NLM)32852815 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hudson, Joshua |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Letter |b optimising response to ustekinumab therapy for patients with Crohn's disease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2020 | ||
| 500 | |a Date Revised 24.11.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Aliment Pharmacol Ther. 2020 Jul;52(1):135-142. - PMID 32412134 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Ustekinumab |2 NLM | |
| 650 | 7 | |a FU77B4U5Z0 |2 NLM | |
| 700 | 1 | |a Herfarth, Hans H |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Edward L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 52(2020), 5 vom: 27. Sept., Seite 906 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2020 |g number:5 |g day:27 |g month:09 |g pages:906 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.15961 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2020 |e 5 |b 27 |c 09 |h 906 | ||